Prescriber's Corner

New Agents in the Treatment of Multiple Myeloma

Beth Faiman,(1) PhD, MSN, APRN-BC, AOCN®, Ali McBride,(2) PharmD, MS, BCPS, BCOP, Hollie Devine,(3) MSN, ANP-BC, Charise Gleason,(4) MSN, NP-BC, AOCNP®, and Sandra Kurtin,(5) RN, MSN, AOCN®, ANP-C, on behalf of the International Myeloma Foundation Nurse Leadership Board

1Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio; 2The University of Arizona Cancer Center, Tuscon, Arizona; 3The Ohio State University Medical Center, Columbus, Ohio; 4Emory University, Atlanta, Georgia

Beth Faiman, PhD, MSN, APRN-BC, AOCN®, Cleveland Clinic Taussig Cancer Institute, Multiple Myeloma Program, 9500 Euclid Avenue, Cleveland, OH 44195.
E-mail: faimanb@ccf.org

Authors' disclosures of potential conflicts of interest are found at the end of this article


J Adv Pract Oncol 2016;7:45–52 | doi: 10.6004/jadpro.2016.7.2.13 | © 2016 Harborside Press®


  



For access to the full length article, please sign in.

Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.